Obagi Medical and Aesthetic Record Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi® saypha® MagIQ™

Rhea-AI Summary

Obagi Medical (NASDAQ: WALD) announced a collaboration with Aesthetic Record to run the ALOHA Real-World Program for Obagi® saypha® MagIQ™, aiming to translate FDA pivotal trial results into everyday practice across multiple providers.

The program leverages Aesthetic Record’s EMR platform used by over 9,000 clinics to capture standardized clinical data, run structured evaluations, and present initial findings at industry conferences.

Positive

• Platform reach: Aesthetic Record used by over 9,000 aesthetic clinics
• Structured real-world data capture across multiple supported practices
• Initial findings to be presented at Aesthetic Next and other conferences

Negative

• None.

Key Figures

Aesthetic clinics on platform: over 9,000 clinics Obagi experience: 35+ years Journal volume/issue: 11(7):487 +5 more

8 metrics

Aesthetic clinics on platform over 9,000 clinics Aesthetic Record user base supporting data capture

Obagi experience 35+ years Obagi Medical legacy in advanced skincare

Journal volume/issue 11(7):487 2025 Gels journal reference on HA filler technologies

Professional brand ranking Top 10 in U.S. Among top 10 professional skin care brands in 2024

Registered shares for resale 9,819,000 shares Class A ordinary shares registered for Novaestiq consideration (424B3)

Cash component $3.0 million Cash in Novaestiq acquisition package (424B3)

Sales threshold $120.0 million Phase 1 net sales level for additional 5.0% share (424B3)

Shareholder participation 72.05% AGM turnout of outstanding ordinary shares on Dec 9, 2025 record date

Market Reality Check

Price: $1.80 Vol: Volume 43,316 is below th...

low vol

$1.80 Last Close

Volume Volume 43,316 is below the 20-day average of 63,956, indicating muted trading ahead of this news. low

Technical Shares at $1.80 are trading below the 200-day MA of $2.07 and well under the 52-week high of $3.54.

Peers on Argus

Peers show mixed moves, with names like ACU up 2.12% and SKIN down 1.89%, sugges...

Peers show mixed moves, with names like ACU up 2.12% and SKIN down 1.89%, suggesting this ALOHA collaboration is stock-specific rather than part of a broad sector rotation.

Historical Context

5 past events · Latest: Feb 06 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 06	ALOHA collaboration	Positive	+3.5%	DermFx partnership to run ALOHA real-world program across its locations.
Feb 05	ALOHA collaboration	Positive	-4.9%	Moxie collaboration for ALOHA real-world evidence across its practices.
Feb 03	Product launch	Positive	+5.3%	Launch of new two-step Lip Therapy protocol in professional channels.
Jan 30	ALOHA collaboration	Positive	+13.5%	VIO Med Spa collaboration for multi-site ALOHA data collection and training.
Jan 28	ALOHA collaboration	Positive	-5.7%	Next Health collaboration integrating MagIQ with wellness protocols.

Pattern Detected

Recent product and ALOHA partnership news has often led to positive moves, but with some notable negative reactions, indicating inconsistent trading responses.

Recent Company History

Over recent weeks, Waldencast has focused on Obagi Medical growth via new products and multiple ALOHA collaborations. Partnerships with VIO Med Spa, Next Health, Moxie, and DermFx all centered on generating real-world evidence for Obagi® saypha® MagIQ™, while a new Lip Therapy protocol launch broadened the portfolio. Market reactions have varied, with some collaborations drawing gains above 10% and others modest declines, showing that similar news does not always produce uniform price outcomes.

Market Pulse Summary

This announcement expands the ALOHA initiative by pairing Obagi® saypha® MagIQ™ with Aesthetic Recor...

Analysis

This announcement expands the ALOHA initiative by pairing Obagi® saypha® MagIQ™ with Aesthetic Record’s network of over 9,000 clinics and data tools to generate real-world evidence. It builds on recent collaborations and product launches that have incrementally shaped Waldencast’s aesthetics strategy. Investors may watch how quickly standardized outcomes data emerges, how widely protocols are adopted across practices, and how this supports commercialization of the MACRO Core Technology-based injectable over time.

Key Terms

electronic medical records, emr, analytics, hyaluronic acid, +3 more

7 terms

electronic medical records technical

"Aesthetic Record is the industry's leading Electronic Medical Records (EMR) and Practice Management platform"

Electronic medical records are digital versions of a patient’s health file created and kept by a single healthcare provider, containing diagnoses, medications, lab results, treatment notes and billing codes. They matter to investors because the software and services that create, store and analyze these records can generate steady revenue, lower provider costs, enable faster decision-making and carry regulatory and cybersecurity risks; think of EMRs as the digital filing cabinet that underpins many healthcare operations.

emr technical

"leveraging its seamless EMR, charting, analytics, and integrated tools used by over 9,000 aesthetic clinics"

An electronic medical record (EMR) is a digital version of a patient’s paper chart used by a single clinic or hospital to store medical history, test results, prescriptions and treatment notes. For investors, EMR systems matter because they drive recurring software and service revenue, affect healthcare providers’ costs and efficiency, and carry regulatory, privacy and interoperability risks that can influence adoption, contract value and long‑term market growth.

analytics technical

"standardized data capture facilitated through the platform's powerful analytics and reporting capabilities"

Analytics involves examining data to identify patterns, trends, and insights that can inform decision-making. For investors, it’s like using a detailed weather forecast to plan for the future—helping them understand potential risks and opportunities. By turning raw information into understandable information, analytics supports smarter, more informed choices in financial activities.

hyaluronic acid medical

"Aesthetics Leadership with Obagi’s Hyaluronic Acid (ALOHA) Program"

A naturally occurring molecule that acts like a tiny sponge, holding water in skin, joints and eyes to keep tissues plump and lubricated. Investors track products containing hyaluronic acid because they power large markets—such as skincare, injectable fillers, eye drops and wound treatments—so demand, regulatory approvals, manufacturing capacity and raw-material costs can meaningfully affect a company’s sales and profit outlook.

injectable medical

"launching this innovative injectable, and we have the technology platform and reach"

A product described as an "injectable" is a medicine or vaccine formulated to be given by needle, syringe, or infusion rather than taken by mouth. For investors it matters because injectables often require specialized manufacturing, cold storage and trained staff to administer, which can raise costs, create supply-chain risks and form higher barriers to competitors—factors that influence a product’s price, market reach and long-term revenue potential.

clinical initiative medical

"The program includes a real-world clinical initiative supplemented by a structured evaluation process"

A clinical initiative is an organized effort by a healthcare company to test, develop, improve or expand medical treatments, procedures or patient programs, often through studies, pilot projects or partnerships. Investors watch these initiatives because they signal how a company plans to create future revenue, reduce costs or gain competitive advantage—like a business testing a new product line to see if it will attract customers and boost sales—and outcomes can affect valuation and regulatory risk.

compliance monitoring technical

"efficient charting, photo documentation, compliance monitoring and performance tracking"

An ongoing process where a company checks that it follows laws, industry rules and its own internal policies, like regular health checkups that catch problems before they worsen. Investors care because effective monitoring lowers the chance of fines, lawsuits, operational disruptions or reputational damage—outcomes that can hurt profits and share prices—while weak monitoring can signal management risk and potential unexpected costs.

AI-generated analysis. Not financial advice.

Aesthetic Record selected as a leading aesthetics EMR and practice management partner due to its commitment to technology innovation, operational efficiency, and supporting thousands of aesthetic practices nationwide

NEW YORK and IRVING, Texas, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Obagi Medical, a leading innovator in physician-dispensed skincare and aesthetic solutions and part of Waldencast plc (NASDAQ: WALD) (“Waldencast” or the “Company”), today announced Aesthetic Record as a key partner for the Aesthetics Leadership with Obagi’s Hyaluronic Acid (ALOHA) Program. Aesthetic Record will help generate real-world data to translate the clinical safety and efficacy demonstrated in FDA pivotal trials into everyday practice across multiple trials and evaluation programs, leveraging its seamless EMR, charting, analytics, and integrated tools used by over 9,000 aesthetic clinics.

“This partnership with Obagi aligns with our mission to enhance the patient experience by equipping practices with best-in-class tools. They're taking a thoughtful, evidence-based approach to launching this innovative injectable, and we have the technology platform and reach to capture how practices translate that information into treating patients day-to-day,” said Tiphany Hall, PhD, Chief Growth Office at Aesthetic Record. “Our users are in high-volume practices, offering a diverse portfolio of treatments, all with efficient charting, photo documentation, compliance monitoring and performance tracking. An integrated experience matters for busy practices. This is the kind of collaborative work that advances the aesthetics industry by combining cutting-edge injectables with streamlined technology and comprehensive skincare protocols to yield better patient outcomes. Obagi’s focus on real-world insights aligns with our mission to empower practices with tools that simplify operations and elevate care.”

The ALOHA Real-World Program is designed to give Aesthetic Record users hands-on experience with Obagi saypha^® MagIQ™ while evaluating complete Obagi protocols. This approach aims to drive patient satisfaction and strengthen relationships between patients and their providers. The program includes a real-world clinical initiative supplemented by a structured evaluation process across multiple Aesthetic Record-supported practices and providers, with standardized data capture facilitated through the platform's powerful analytics and reporting capabilities.

Aesthetic Record will present initial findings at the upcoming Aesthetic Next conference, highlighting the benefits of the new protocols and product within the Aesthetic Record ecosystem. Results will also be presented at key industry conferences to demonstrate the real-world impact of introducing this innovative injectable across thousands of aesthetic practices powered by Aesthetic Record.

“Partnering with Aesthetic Record is a clear statement of our intent to launch this new injectable beyond the typical approaches,” said Drew Fine, U.S. General Manager, Professional Channel. “By leveraging Aesthetic Record’s advanced technology platform, we can drive launch success in a more efficient and scalable manner, capturing high-quality real-world data faster and more comprehensively than traditional methods. The ALOHA program will serve as a platform for a differentiated launch strategy and underscore Obagi Medical’s commitment to delivering innovative products across every facet of skincare and now injectable aesthetics.”

Obagi^® saypha^® MagIQ™, developed by Croma-Pharma GmbH, utilizes proprietary MACRO Core Technology to create a stable three-dimensional hyaluronic acid matrix. The technology is designed to deliver natural-looking results with category-leading performance, including high usable HA content upon injection, consistent gel distribution, and a predictable injection force and swelling profile¹.

For more information about ALOHA, visit https://obagi-professional.com.

About Obagi Medical
Obagi Medical is an industry-leading, advanced skincare line rooted in research and skin biology, with a legacy of 35+ years of experience. Initially known for its leadership in the treatment of hyperpigmentation with the Obagi Nu-Derm^® System, Obagi Medical products are designed to address a variety of skin concerns, including premature aging, photodamage, skin discoloration, acne, and sun damage. As the fastest-growing professional skincare brand in the U.S. in 2024,² Obagi Medical empowers individuals to achieve healthy, beautiful skin. More information about Obagi Medical is available on the brand's website, https://www.obagi.com.

About Aesthetic Record
Aesthetic Record is the industry's leading Electronic Medical Records (EMR) and Practice Management platform built exclusively for medical aesthetics. Trusted by thousands of practices, from startups to enterprise groups, Aesthetic Record streamlines clinical documentation, patient engagement, operations, and financial performance within a single, integrated ecosystem. By empowering practices with end-to-end solutions, including marketing automation, e-commerce, compliance, and payment processing, Aesthetic Record helps providers simplify, scale, and succeed at the speed of aesthetics.

About Waldencast plc
Founded by Michel Brousset and Hind Sebti, Waldencast’s ambition is to build a global best-in-class beauty and wellness operating platform by developing, acquiring, accelerating, and scaling conscious, high-growth purpose-driven brands. Waldencast’s vision is fundamentally underpinned by its brand-led business model that ensures proximity to its customers, business agility, and market responsiveness, while maintaining each brand’s distinct DNA. For more information please visit: https://ir.waldencast.com.

Media Contact:
obagi@behrmancesa.com

Source: Waldencast plc

¹ Puljic A, Frank K, Cohen J, Otto K, Mayr J, Hugh-Bloch A, Kuroki-Hasenöhrl, D. A Scientific Framework for Comparing Hyaluronic Acid Filler Crosslinking Technologies. Gels. 2025; 11(7):487
² Among the Top 10 Professional Skin Care Brands in the U.S., According to Kline’s 2024 Global Professional Skin Care Series (China, Europe and the U.S.)

FAQ

What is the ALOHA program announced by Obagi Medical (WALD) on Feb 17, 2026?

The ALOHA program is a real-world clinical initiative to evaluate Obagi saypha MagIQ in practice settings. According to Obagi Medical, it uses Aesthetic Record’s EMR to collect standardized outcomes across multiple clinics and support structured evaluations and reporting.

How many clinics will Aesthetic Record reach for Obagi’s ALOHA real-world study?

Aesthetic Record serves over 9,000 aesthetic clinics, offering broad real-world reach for data collection. According to Aesthetic Record, its EMR, charting, photo documentation, and analytics enable standardized capture across high-volume practices for the ALOHA program.

What product is being evaluated in the ALOHA program by Obagi Medical (WALD)?

The program evaluates Obagi® saypha® MagIQ™, a hyaluronic acid injectable using MACRO Core Technology. According to Obagi Medical, the technology aims for high usable HA content, consistent gel distribution, and predictable injection and swelling profiles.

Will ALOHA program results be shared publicly by Obagi Medical (WALD)?

Yes, initial results will be presented publicly at industry conferences, starting with Aesthetic Next. According to Obagi Medical, findings will highlight protocol benefits and real-world impact across practices using Aesthetic Record’s analytics.

How does the Obagi and Aesthetic Record collaboration aim to support product launch for WALD?

The collaboration aims to accelerate launch by capturing high-quality real-world evidence and practice-level adoption metrics. According to Obagi Medical, leveraging Aesthetic Record’s platform enables faster, scalable data capture and structured evaluation to support a differentiated launch strategy.